Boulder Ventures

Boulder Ventures Ltd. is a distinguished venture capital firm established in 1995, focusing on early-stage investments in high-potential Information Technology and Biotechnology companies. The firm strategically targets companies within the Colorado Front Range and the Mid-Atlantic region, leveraging its deep regional expertise and extensive network of entrepreneurs and investors. Boulder Ventures aims to identify and support innovative companies with strong technical and scientific foundations, fostering their growth and market leadership.

The firm's investment strategy is characterized by its commitment to being the inaugural professional investor in its portfolio companies, often participating in multiple funding rounds from Seed to Series B stages. Boulder Ventures has a notable track record, having invested in 61 companies, which have led to 28 exits and 10 initial public offerings (IPOs). Across its flagship funds, the firm has raised approximately $466 million, demonstrating its significant presence and capability in the venture capital landscape.

Boulder Ventures boasts a diverse portfolio with several successful exits and promising current investments. Notable exited companies include Array BioPharma, which was acquired by Pfizer for $11.8 billion, LeftHand Networks, acquired by HP, and Wall Street on Demand, acquired by Goldman Sachs. The firm's current portfolio features innovative companies such as Ambrosia Biosciences, a GLP-1 developer, OnKure Therapeutics, focused on cancer precision medicines, and Stardog, an enterprise data unification platform. Recent investments also include companies like Comeryx in financial software and RapidFort in software supply chain security.

The leadership team at Boulder Ventures comprises experienced general partners, including founder Kyle Lefkoff, who brings over 38 years of venture capital experience. He is joined by Peter Roshko, Kishen Mangat, and Jonathan Perl, along with Chief Financial Officer Matthew Paul. The partners collectively possess extensive backgrounds in guiding companies through critical growth stages, strategic exits, and fostering innovation across the IT and life sciences sectors.